Alkeus Pharmaceuticals Announces Positive Gildeuretinol Data Will Be Presented During the 12th International FLORetina ICOOR Congress December 5–8 in Florence, Italy
05 déc. 2024 08h30 HE
|
Alkeus Pharmaceuticals
CAMBRIDGE, Mass., Dec. 05, 2024 (GLOBE NEWSWIRE) -- Alkeus Pharmaceuticals, Inc. today announced that results from its clinical studies of investigational oral gildeuretinol for the treatment of...
Alkeus Pharmaceuticals Receives FDA Rare Pediatric Disease and Fast Track Designations for Gildeuretinol as a Treatment for Stargardt Disease
18 nov. 2024 09h16 HE
|
Alkeus Pharmaceuticals
Alkeus Pharmaceuticals, Inc. receives FDA Rare Pediatric Disease and Fast Track designations for gildeuretinol as a treatment for Stargardt Disease
Topline Results from Alkeus Pharmaceuticals’ Study of Oral Gildeuretinol Demonstrate Significant Trend in Slowing GA Progression and Visual Function Improvement
23 oct. 2024 09h00 HE
|
Alkeus Pharmaceuticals
Alkeus Pharmaceuticals, Inc., today announced that results from its study of gildeuretinol in geographic atrophy were presented at AAO 2024.
Alkeus Pharmaceuticals Announces Presentation of a TEASE-3 Study Update Showing Progression Stalled in Early-Stage Stargardt Disease Patients Treated with Gildeuretinol
18 juil. 2024 10h20 HE
|
Alkeus Pharmaceuticals
Alkeus Pharmaceuticals announces presentation of a TEASE-3 study update showing progression stalled in early-stage Stargardt disease
Alkeus Pharmaceuticals Appoints Tamara Dillon as Chief Human Resources Officer
16 juil. 2024 09h00 HE
|
Alkeus Pharmaceuticals
Alkeus Pharmaceuticals appoints Tamara Dillon as Chief Human Resources Officer
Accomplished Biotech Leader Michel Dahan Joins Alkeus as President and CEO
02 juil. 2024 08h30 HE
|
Alkeus Pharmaceuticals
Alkeus Pharmaceuticals, Inc. announced today that Michel Dahan has joined the company as President and Chief Executive Officer.